A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV.

The FDA has approved Gilead Sciences' lenacapavir, sold as Yeztugo, as a biannual injection to prevent HIV, signaling a ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV, a move the ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

aaSouth African Centre for Epidemiological Modelling and Analysis, Centre for Epidemic Response and Innovation, School for Data Science and Computational Thinking, Stellenbosch University, ...

On June 2, Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target. The analyst’s bullish stance follows the company presenting data ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...

The Trump administration terminated $258 million in funding to the Center for HIV/AIDS Vaccine Development (CHAVD) Friday, including $129 million for Duke. Researchers were told that the ...